Skip to main content
. Author manuscript; available in PMC: 2020 Aug 1.
Published in final edited form as: Angiogenesis. 2019 Jan 14;22(3):369–382. doi: 10.1007/s10456-019-09662-4

Fig. 2.

Fig. 2.

Anti-Scg3 mAb to treat OIR via intravitreal injection. Anti-Scg3 ML78.2 mAb (4 μg/eye), control mouse IgG1, aflibercept (2 μg/eye) or PBS was injected at P14. a Representative images of flat-mount OIR retina. Arrows indicate neovascularization and NV tufts. b Retinal neovascularization. c NV tufts. d Branch points. e Avascular area. n= 10 eyes (PBS), n= 7 eyes (control IgG), n=11 eyes (aflibercept), n= 9 eyes (anti-Scg3 mAb). Bar = 100 μm (zoom-in). ± SEM, one-way ANOVAtest.